A Phase 3 interventional study of Neuronox and Botox in Essential Blepharospasm, sponsored by Medy-Tox. Completed. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-07-13.
Sponsored by Medy-Tox · Phase 3, Interventional, and Treatment
This clinical study evaluates the efficacy and safety of Neuronox compared with Botox in adults with essential blepharospasm.
Subjects are randomly assigned into the two groups at the ratio of 1:1. The purpose of study is to confirm the non-inferiority of Neuronox to Botox in terms of the efficacy and safety in subjects with essential blepharospasm.
Exclusion Criteria:
Botulinum Toxin Type A for injection
Drug: Neuronox
Botulinum Toxin Type A for injection
Drug: Botox
Clostridium Botulinum Toxin A 100 U
Also known as: Botulinum Toxin Type A for injection
Clostridium Botulinum Toxin A 100 U
Also known as: Botulinum Toxin Type A for injection
JRS (Jankovic Rating Scale) sum-score
Change from baseline at 4 week for the JRS (Jankovic Rating Scale) sum-score
Time frame: From baseline at 4 week
No study locations are listed for this record.
Plan to share: Undecided
No publications or documents are linked to this record.
This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Medy-Tox